These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 35122335)

  • 1. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment.
    Nahum Y; Mimouni M; Livny E; Bahar I; Hodak E; Leshem YA
    Br J Ophthalmol; 2020 Jun; 104(6):776-779. PubMed ID: 31554632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
    Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
    Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.
    Felfeli T; Georgakopoulos JR; Jo CE; Mimouni M; Piguet V; Drucker AM; Yeung J; Chan CC
    Cornea; 2022 Oct; 41(10):1242-1247. PubMed ID: 34843182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab induced ocular surface disease: A prospective case series.
    Pradhan SP; Sadiq SN; Cartes C; Babakinejad P; Ball S; Reynolds NJ; Meggitt S; Figueiredo FC
    Eur J Ophthalmol; 2024 May; 34(3):691-699. PubMed ID: 37644849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
    Achten R; Thijs J; van der Wal M; van Luijk C; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Allergy; 2023 Aug; 78(8):2266-2276. PubMed ID: 36934403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dupilumab-related blepharoconjunctivitis: Recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: Which management approach?].
    Doan S; Arnould L; Febvay C; Fournié P; Gueudry J; Labalette P; Ouilhon C; Tran TH; Vabres B; Barbarot S; Bouaziz JD; Du-Thanh A; Jachiet M; Seneschal J; Soria A; Staumont-Sallé D; Baudouin C; Mortemousque B
    J Fr Ophtalmol; 2022 Mar; 45(3):277-287. PubMed ID: 35078645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjunctivitis in patients with atopic dermatitis treated with dupilumab.
    Ferreira S; Torres T
    Drugs Context; 2020; 9():. PubMed ID: 32426016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
    Wu D; Daniel BS; Lai AJX; Wong N; Lim DKA; Murrell DF; Lim BXH; Mehta JS; Lim CHL
    Surv Ophthalmol; 2022; 67(5):1419-1442. PubMed ID: 35181280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.